首页> 外文OA文献 >Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

【2h】

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

机译：重组人透明质酸酶促进皮下输注人免疫球蛋白对原发性免疫缺陷的长期耐受性，安全性和有效性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Richard L. Wasserman; Isaac Melamed; Mark R. Stein; Werner Engl; Marlies Sharkhawy; Heinz Leibl; Jennifer Puck; Arye Rubinstein; Lisa Kobrynski; Sudhir Gupta; Andrew J. Grant; Anoshie Ratnayake; Wendell G. Richmond; Joseph Church; Leman Yel; David Gelmont;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency [J] . Wasserman Richard L., Melamed Isaac, Stein Mark R., Journal of Clinical Immunology . 2016,第6期

机译：重组人透明质酸酶促进皮下输注人免疫球蛋白对原发性免疫缺陷的长期耐受性，安全性和有效性
2. EFFICACY OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS INFUSION OF IMMUNOGLOBULIN G (IGHy) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES: INFECTIONS OVER TIME [J] . Wasserman Richard L., Stein Mark, Kobrynski Lisa, Journal of Clinical Immunology . 2016,第3期

机译：重组人透明质酸酶促免疫球蛋白G（IGHy）皮下注射在原发性免疫缺陷疾病中的疗效：随着时间的推移感染
3. LONG TERM SAFETY, EFFICACY AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE [RHUPH20]-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNOGLOBULIN G (IGG) (HYQVIA; IGHY) IN PATIENTS AGED >= 16 YEARS WITH PRIMARY IMMUNODEFICIENCIES (PID) [J] . Wasserman Richard L., Stein Mark, Kobrynski Lisa, Journal of Clinical Immunology . 2015,第3期

机译：≥16岁（≥16岁）的初次发病的老年患者中，重组人透明质酸酶[RHUPH20]促成免疫球蛋白G（IGG）（HYQVIA; IGHY）的皮下注射（SC）的长期安全性，有效性和耐受性
4. Safety Profile of subcutaneously Immunoglobulin G (SUBCUVIA) treatment in Children <= 12 Years with primary Immunodeficiencies [C] . Permin H., Herlin T., Gajek H., European Congress of Immunology . 2009

机译：皮下免疫球蛋白G（Subcuvia）治疗儿童的安全性<= 12年，主要免疫缺失
5. Safety Supervision System Design and Implications for Continuous Subcutaneous Insulin Infusion (CSII) in T1DM [D] . Hughes, Colleen Suzanne 2011

机译：T1DM中连续皮下注射胰岛素（CSII）的安全性监控系统设计及其意义
6. Long-Term Tolerability Safety and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency [O] . Richard L. Wasserman, Isaac Melamed, Mark R. Stein, -1

机译：重组人透明质酸酶促进皮下输注人免疫球蛋白对原发性免疫缺陷的长期耐受性安全性和功效
7. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases [O] . Richard L Wasserman 2017

机译：重组人透明质酸酶促进的皮下免疫球蛋白输注原发性免疫缺陷疾病

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

著录项

引文网络

相似文献

相关主题

期刊订阅